Table 3. Effect of glycemic control (stringent or less stringent) on unfavourable TB treatment outcomes, summarized as unadjusted relative risk (RR)* [40–47].
Study ID | Reference group | Exposed group | Unadjusted RR | 95% CI |
---|---|---|---|---|
All unfavourable end (TB) treatment outcome | ||||
Chiang CY_2015_Plos One | Poor glycemic control (HbA1c>9) | Less stringent glycemic control (HbA1c 7–9) | 1.53 | 0.96, 2.46 |
Stringent glycemic control (HbA1c<7) | 1.89 | 1.12, 3.20 | ||
Mi F_2013_TMIH^ | Poor glycemic control (FPG>10mmol/l) | Less stringent glycemic control (FPG7-10mmol/l) | 0.91 | 0.18, 4.43 |
Stringent glycemic control (FPG<7mmol/l) | 1.03 | 0.21, 5.07 | ||
Magee MJ_2013_International J of Infectious diseases | Poor glycemic control (no specific criteria) | Glycemic control | 1.08 | 0.54, 2.16 |
Nandakumar KV_2013_Plos One | Poor glycemic control (FBG>100 mg/dl and PPBS/RBG>140 mg/dl) | Glycemic control | 0.52 | 0.25, 1.07 |
Tabarsi P_2014_Journal of Diabetes and Metabolic Disorder | Poor glycemic control (HbA1c≥6.5) | Glycemic control | 1.13 | 0.2, 6.44 |
Yoon YS_2017_Thorax | Poor glycemic control (HbA1c≥7) | Glycemic control | 0.55 | 0.22, 1.36 |
Mahishale_2017_Iran J MS | Poor glycemic control (HbA1c≥7) | Glycemic control | 0.18 | 0.09, 0.36 |
Culture non-conversion at 2 months | ||||
Park SW_2012_Eur J ClinMicrobiol Infect Dis | Poor glycemic control (HbA1c>7) | Glycemic control | 0.62 | 0.14, 2.71 |
Yoon YS_2017_Thorax | Poor glycemic control (HbA1c≥7) | Glycemic control | 0.23 | 0.05, 0.94 |
Sputum smear non-conversion at 2 months | ||||
Mi F_2013_TMIH^ | Poor glycemic control (FPG>10mmol/l) | Less stringent glycemic control (FPG7-10mmol/l) | 1.50 | 0.57, 3.90 |
Stringent glycemic control (FPG<7mmol/l) | 0.65 | 0.19, 2.15 | ||
Nandakumar KV_2013_Plos One | Poor glycemic control (FBS>100 mg/dl and PPBS/RBS>140 mg/dl) | Glycemic control | 0.99 | 0.65, 1.51 |
Mahishale_2017_Iran J MS | Poor glycemic control (HbA1c≥7) | Glycemic control | 0.12 | 0.06, 0.23 |
*data extracted from the narrative text/tables;
^End IP and end treatment outcomes reported among those with glycemic status at 2 months and 6 months respectively